Topic

Arikayce (amikacin liposome inhalation)

A collection of 33 issues

How to Get Arikayce Covered by Blue Cross Blue Shield in Ohio: Renewal Guide, Appeals Timeline, and Documentation Checklist

Quick Answer: Arikayce (amikacin liposome inhalation) renewals with Blue Cross Blue Shield Ohio require updated culture results, clinical response documentation, and safety monitoring reports every 6-12 months. Start renewal requests 30-60 days before expiration. Submit via Availity portal for commercial plans or CarelonRx for MyCare Ohio. If denied, you have
5 min read

Resources to Get Arikayce (Amikacin Liposome Inhalation) Approved with Cigna in Pennsylvania: Complete Forms, Portals & Contact Guide

Answer Box: Getting Arikayce Covered by Cigna in Pennsylvania Fastest path to approval: Your pulmonologist must submit a prior authorization request through Cigna's provider portal or call 1-800-882-4462, documenting refractory MAC lung disease with ≥6 months of failed multi-drug therapy and positive cultures. First step today: Contact your
5 min read

How to Get Arikayce (Amikacin Liposome Inhalation) Covered by Cigna in Washington: Prior Authorization, Appeals, and Cost-Saving Strategies

Answer Box: Getting Arikayce Covered by Cigna in Washington Cigna requires prior authorization for Arikayce (amikacin liposome inhalation) with strict criteria: adult MAC lung disease, documented failure after ≥6 months of guideline-based multidrug therapy, and prescription by a pulmonologist or infectious disease specialist. If denied, you have 180 days to
6 min read

How to Get Arikayce Covered by Cigna in Ohio: Complete Prior Authorization and Appeal Guide

Answer Box: Getting Arikayce Covered by Cigna in Ohio Cigna requires prior authorization for Arikayce (amikacin liposome inhalation) with specific criteria: refractory MAC lung disease after ≥6 months of combination therapy, amikacin-susceptible cultures, and specialist oversight. First step: Gather baseline audiogram, culture results, and documentation of failed standard therapy. Submit
6 min read

How to Get Arikayce Covered by UnitedHealthcare in Michigan: Complete Prior Authorization and Appeals Guide

Answer Box: Getting Arikayce Covered by UnitedHealthcare in Michigan Eligibility: Arikayce requires prior authorization through OptumRx for refractory MAC lung disease after ≥6 months of failed combination therapy. Fastest approval path: Submit complete PA request with documented treatment failure, culture results, and specialist oversight. First step today: Contact your pulmonologist
5 min read

How to Get Arikayce Covered by Blue Cross Blue Shield in Washington: Complete Guide to Prior Authorization, Appeals, and State Review

Answer Box: Getting Arikayce Covered by Blue Cross Blue Shield in Washington Arikayce (amikacin liposome inhalation) requires prior authorization from Blue Cross Blue Shield plans in Washington for refractory MAC lung disease. You need documented failure of at least 6 months of standard multidrug therapy with persistent positive cultures. The
6 min read

Renewing Arikayce Approval with UnitedHealthcare in Ohio: Documentation Requirements and Timeline Guide

Answer Box: Renewing Arikayce Coverage in Ohio UnitedHealthcare requires annual reauthorization for Arikayce (amikacin liposome inhalation) in Ohio. Start your renewal 30-60 days before expiration with negative sputum cultures or physician attestation of continued benefit, current susceptibility testing, and evidence of ongoing combination therapy. Submit through the OptumRx Provider Portal
5 min read

Arikayce Coverage with UnitedHealthcare in California: Complete Guide to Prior Authorization, Appeals, and Approval Timeline

Answer Box: Getting Arikayce Covered by UnitedHealthcare in California Arikayce requires prior authorization from UnitedHealthcare through OptumRx. To qualify, you must have refractory MAC lung disease with positive cultures after at least 6 months of combination therapy (macrolide + ethambutol + rifamycin). Your fastest path: Have your pulmonologist or infectious disease specialist
5 min read